Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial-Reference-Cited by-同舟云学术

Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial

Published:2023-10-21 Issue:48 Volume:44 Page:5163-5166
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:

Author:

Pandey Ambarish¹²^ORCID,Kolkailah Ahmed A¹²^ORCID,Cosentino Francesco³^ORCID,Cannon Christopher P⁴^ORCID,Frederich Robert C⁵^ORCID,Cherney David Z I⁶^ORCID,Dagogo-Jack Samuel⁷^ORCID,Pratley Richard E⁸^ORCID,Cater Nilo B⁹^ORCID,Gantz Ira¹⁰,Mancuso James P⁵,McGuire Darren K¹²^ORCID

Affiliation:

1. Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center , 5323 Harry Hines Blvd, Dallas, TX 75390-9047 , USA

2. Parkland Health and Hospital System, 5200 Harry Hines Blvd, Dallas, TX 75235 , USA

3. Unit of Cardiology, Department of Medicine, Karolinska Institute and Karolinska University Hospital , Stockholm , Sweden

4. Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School , Boston, MA , USA

5. Pfizer Inc , Groton, CT , USA

6. Division of Nephrology, University Health Network, University of Toronto , Toronto, ON , Canada

7. University of Tennessee Health Science Center , Memphis, TN , USA

8. AdventHealth Translational Research Institute , Orlando, FL , USA

9. Pfizer Inc , New York, NY , USA

10. Merck & Co., Inc , Rahway, NJ , USA

Funder

Merck Sharp & Dohme LLC

Merck & Co., Inc.